Hemolysis, elevated liver functions and low platelets (HELLP syndrome): Does the use of dexamethasone in the postpartum period improve maternal outcome?

Hemolysis, elevated liver functions and low platelets (HELLP syndrome): Does the use of dexamethasone in the postpartum period improve maternal hospital stay and complications?

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610001007022

Enrollment

Registered

2010-11-18

Start date

2008-10-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To establish if the use of corticosteroids improve the outcome of patients with HELLP syndrome

Interventions

Patients with HELLP syndrome was randomised to receive either dexamethasone or no dexamethasone in postpartum peroid. the dose of dexamethasone was 24 mg on day 1, 16mg on day2 and 12 mg on day 3 and it was given intravenously.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

HELLP syndrome according to Tennessee criteria Haptoglobin in all cases to confirm hemolysis

Exclusion criteria

Partial hemolysis, elevated liver functions and low platelet (HELLP) syndrome Thrombotic thrombocytopenic purpura (TTP) Ideopatic thrombocytopenic purpura (ITP) Hemolytic uremic syndrome (HUS) Acute fatty liver of pregnancy Cholestasis of pregnancy

Outcome results